Pharmaron Beijing Co., Ltd. (3759) has issued its unaudited Third Quarterly Report for 2025. During the first three quarters of 2025, the company recorded revenue of RMB10,085.62 million, up 14.38% compared with the same period in the previous year. Net profit attributable to owners of the parent reached RMB1,140.91 million, reflecting a 19.76% decrease over the prior-year period. Excluding non-recurring items, net profit attributable to owners of the parent grew 32.04% year-on-year, and non-IFRS adjusted net profit was RMB1,226.55 million, marking a 10.76% increase.
According to the announcement, service segments’ performance varied. Laboratory services generated revenue of RMB6,003.75 million, a 15.04% rise year-on-year, while CMC (small molecule CDMO) services grew by 15.99% to RMB2,292.70 million. Clinical development services advanced 10.26% to RMB1,439.89 million. The biologics and cell/gene therapy segment contributed RMB336.27 million, up 8.13% from a year earlier. Geographically, revenue from North American customers accounted for 63.58% of total revenue, while the European market (including the U.K.) contributed 18.66% and China 15.29%.
Newly signed purchase orders increased by more than 13% year-on-year in the first three quarters, led by steady expansion in laboratory services and around 20% growth in CMC (small molecule CDMO) services. Based on existing orders, the company expects its full-year revenue to rise by 12% to 16% compared with the prior year, noting that this expectation does not constitute a formal profit forecast.
Cash flow from operating activities improved by 37.59% year-on-year to RMB2,436.10 million, supported by increased revenue. Looking ahead, the company announced a strategic collaboration with Zhejiang University on artificial intelligence and life sciences, and it also completed an acquisition in real-world evidence and health economics research. These initiatives aim to drive continued business development across diverse services and regions, reinforcing Pharmaron’s integrated offerings in the global pharmaceutical services market.